Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18457330rdf:typepubmed:Citationlld:pubmed
pubmed-article:18457330lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0543467lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C1513882lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0278678lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C1253959lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:18457330lifeskim:mentionsumls-concept:C1514923lld:lifeskim
pubmed-article:18457330pubmed:issue2lld:pubmed
pubmed-article:18457330pubmed:dateCreated2008-7-15lld:pubmed
pubmed-article:18457330pubmed:abstractTextThe treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients. The current study presents the authors' 20-year experience administering this immunotherapeutic agent.lld:pubmed
pubmed-article:18457330pubmed:languageenglld:pubmed
pubmed-article:18457330pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18457330pubmed:citationSubsetAIMlld:pubmed
pubmed-article:18457330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18457330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18457330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18457330pubmed:statusMEDLINElld:pubmed
pubmed-article:18457330pubmed:monthJullld:pubmed
pubmed-article:18457330pubmed:issn0008-543Xlld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:SherryRichard...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:YangJames CJClld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:SteinbergSeth...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:KammulaUdai...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:RosenbergStev...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:RoyalRichard...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:HughesMarybet...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:SmithFranz...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:KlapperJacob...lld:pubmed
pubmed-article:18457330pubmed:authorpubmed-author:DowneyStephan...lld:pubmed
pubmed-article:18457330pubmed:issnTypePrintlld:pubmed
pubmed-article:18457330pubmed:day15lld:pubmed
pubmed-article:18457330pubmed:volume113lld:pubmed
pubmed-article:18457330pubmed:ownerNLMlld:pubmed
pubmed-article:18457330pubmed:authorsCompleteYlld:pubmed
pubmed-article:18457330pubmed:pagination293-301lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:meshHeadingpubmed-meshheading:18457330...lld:pubmed
pubmed-article:18457330pubmed:year2008lld:pubmed
pubmed-article:18457330pubmed:articleTitleHigh-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.lld:pubmed
pubmed-article:18457330pubmed:affiliationCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.lld:pubmed
pubmed-article:18457330pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18457330lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18457330lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18457330lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18457330lld:pubmed